Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.47 |
| ▸ | NQO2 | P16083 | 6/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140163 | 0.88 | LMNA (0.50) | CYP19A1HTR2CDRD2DRD3 | |
| SCHEMBL9749054 | 0.88 | LMNA (0.50) | CYP19A1HTR2CDRD2DRD3 | |
| SCHEMBL9749057 | 0.88 | LMNA (0.50) | CYP19A1HTR2CDRD2DRD3 | |
| SCHEMBL1180151 | 0.84 | OPRM1 (0.47) | HTR2AHTR2CHTR2BDRD2DRD3 | |
| SCHEMBL9688445 | 0.81 | DRD2 (0.53) | MTNR1ACYP19A1CYP11B1MTNR1BNQO2 | |
| SCHEMBL30715531 | 0.81 | MTNR1A (0.49) | MTNR1ACYP19A1CYP11B1MTNR1BNQO2 | |
| SCHEMBL30715541 | 0.81 | MTNR1A (0.49) | MTNR1ACYP19A1CYP11B1MTNR1BNQO2 | |
| SCHEMBL13363972 | 0.81 | DRD2 (0.53) | MTNR1ACYP19A1CYP11B1MTNR1BNQO2 | |
| SCHEMBL326892 | 0.80 | MTNR1A (0.54) | MTNR1ACYP19A1CYP11B1MTNR1BNQO2 | |
| SCHEMBL9813925 | 0.79 | DRD1 (0.46) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612061-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090076030-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-20090075982-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-03-19 | — | — | US | disclosed |
| US-7465733-B2 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-12-16 | — | — | US | disclosed |
| EP-1710240-B1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | SERVIER LAB (FR) | 2007-12-05 | — | — | EP | disclosed |
| US-20060229318-A1 | Piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-12 | — | — | US | disclosed |
| EP-1710240-A1 | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | Les Laboratoires Servier (FR) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075982-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | MTNR1A 156/4885CYP19A1 518/4885CYP11B1 366/4885 |
| US-20090076030-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | MTNR1A 156/4885CYP19A1 518/4885CYP11B1 366/4885 |
| US-20060229318-A1 | Piperazine compounds | HTR7, HTR5A, NPY5R | MTNR1A 156/4885CYP19A1 518/4885CYP11B1 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.